Literature DB >> 19596111

The tide of antimicrobial resistance and selection.

Mark H Wilcox1.   

Abstract

The cumulative ecological damage, both to the individual patient and to patient populations, secondary to antibiotic prescribing is increasingly recognised. The impact of antibiotics on pathogens and normal flora should be a criterion for antimicrobial selection. Measures to reduce the use of third-generation cephalosporins and fluoroquinolones should be considered. Increased reliance on carbapenems may accelerate the emergence of extremely resistant isolates, and these antimicrobials should be restricted to key scenarios. There is a clear need for new agents with novel modes of action and low ecological damage potential to treat nosocomial infections. Tigecycline has a spectrum of activity that theoretically may reduce the selection pressure for key nosocomial pathogens, and represents an alternative to carbapenems. Further studies are needed to confirm this potentially low selection pressure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596111     DOI: 10.1016/S0924-8579(09)70550-3

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  19 in total

1.  Severe community-acquired pneumonia and positive urinary antigen test for S. pneumoniae: amoxicillin is associated with a favourable outcome.

Authors:  V Blanc; A Mothes; A Smetz; I Timontin; M D Guardia; A Billiemaz; J Dellamonica; M Vassallo; D Néri; S Chadapaud; A-L Toyer; P Del Guidice; A Fribourg; S Léotard; I Nicolle; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-17       Impact factor: 3.267

2.  Time from onset of SIRS to antibiotic administration and outcomes after subarachnoid hemorrhage.

Authors:  Elan L Guterman; Hooman Kamel; Carmil Azran; Maulik P Shah; J Claude Hemphill; Wade S Smith; Babak B Navi
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

3.  Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.

Authors:  J Pradelli; K Risso; F G de Salvador; E Cua; R Ruimy; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-02       Impact factor: 3.267

4.  The knowledge mobilisation challenge: does producing evidence lead to its adoption within dentistry?

Authors:  T L Goodwin; P R Brocklehurst; L Williams
Journal:  Br Dent J       Date:  2018-02-02       Impact factor: 1.626

5.  Resistance to antimicrobial drugs in Ghana.

Authors:  Mercy J Newman; Enoch Frimpong; Eric S Donkor; Japheth A Opintan; Alex Asamoah-Adu
Journal:  Infect Drug Resist       Date:  2011-12-21       Impact factor: 4.003

Review 6.  Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin.

Authors:  Christian Eckmann; M Dryden
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

7.  Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions.

Authors:  Christian Eckmann; M Dryden; P Montravers; R Kozlov; G Sganga
Journal:  Eur J Med Res       Date:  2011-03-28       Impact factor: 2.175

8.  Antibiotic prescription: An oral physician's point of view.

Authors:  Mahendra Patait; N Urvashi; M Rajderkar; S Kedar; Kinjal Shah; Reeta Patait
Journal:  J Pharm Bioallied Sci       Date:  2015 Apr-Jun

Review 9.  Transfer of multidrug-resistant bacteria between intermingled ecological niches: the interface between humans, animals and the environment.

Authors:  Paulo Martins da Costa; Luís Loureiro; Augusto J F Matos
Journal:  Int J Environ Res Public Health       Date:  2013-01-14       Impact factor: 3.390

10.  Exposure assessment of extended-spectrum beta-lactamases/AmpC beta-lactamases-producing Escherichia coli in meat in Denmark.

Authors:  Luís P Carmo; Liza R Nielsen; Paulo M da Costa; Lis Alban
Journal:  Infect Ecol Epidemiol       Date:  2014-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.